Weitai Medical-B (02235) LinX continuous glucose monitoring system approved for marketing in Brazil

Zhitong Finance App News, Weitai Medical-B (02235) announced that the Group's LinX continuous glucose monitoring system was recently approved for marketing in Brazil and is suitable for continuous dynamic blood sugar monitoring in adults and children.

The company's LinX continuous glucose monitoring system was approved for listing in Brazil, which will greatly strengthen the company's market layout in Latin America and lay a solid foundation for large-scale expansion of international business and revenue growth. In the future, the company will continue to focus on the global development of diabetes monitoring, treatment and management methods, and continue to promote technological and product innovation in related fields.